UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/528,150	03/17/2005	Takeshi Kawazoe	2005_0459A	2807
	7590 07/01/200 , LIND & PONACK, I	EXAMINER		
1030 15th Street, N.W., Suite 400 East Washington, DC 20005-1503			JAVANMARD, SAHAR	
			ART UNIT	PAPER NUMBER
			1617	
			MAIL DATE	DELIVERY MODE
			07/01/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/528,150	KAWAZOE ET AL.	
Examiner	Art Unit	

zororo mor mig or an Appour ziror	Examiner	Art Unit					
	SAHAR JAVANMARD	1617					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
THE REPLY FILED <u>26 May 2009</u> FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. I. ☑ The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time							
periods: a) The period for reply expires 3_months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO.							
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exte Notice of Appeal has been filed, any reply must be filed w AMENDMENTS 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the					
3. The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co (b) They raise the issue of new matter (see NOTE belo (c) They are not deemed to place the application in bel appeal; and/or (d) They present additional claims without canceling a	nsideration and/or search (see NOT ow); tter form for appeal by materially rec corresponding number of finally reje	E below); ducing or simplifying t					
NOTE: (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).							
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE		l be entered and an e	xplanation of				
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 	d sufficient reasons why the affidavi	t or other evidence is	necessary and				
P. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).							
10. ☐ The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attach	ed.				
11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: <u>See Continuation Sheet.</u>							
12. ☐ Note the attached Information <i>Disclosure Statement</i>(s).13. ☐ Other: References in IDS of 5/26/09 have been consider							
/SREENI PADMANABHAN/ Supervisory Patent Examiner, Art Unit 1617	/S. J./ Examiner, Art Unit 1617						

Continuation of 11. does NOT place the application in condition for allowance because: Applicant's arguments are not persuasive. First, Applicant contends that the stage for treating keloid or scar is completely different between the instant invention and the C-S reference. This argument is not persuasive because it is not commensurate in scope of the claimed invention. There is no limitation set forth in the claims that the wound must be "open" as set forth in Applicant's arguments. Specifically, the claims recite "...in a course of therapy of wound or dermal injury...", which in Examiner's opinion includes a wound that is healed. It is near the end of the course of dermal injury. Additionally, Applicant continues to argue that the C-S reference does not teach "topical application" of acetylsalicylic acid. This argument is not persuasive because it is not commensurate in scope of the claimed invention. As set forth in the claims, there is no limitation as to the route of administration of the acetylacetic acid, therefore, the teachings of C-S read on the instant claims.